Form D · Biotechnology
Kanyos Bio, Inc.
San Francisco, CA · CIK 0001644743
Offering snapshot reported Jun 12, 2015 · SEC filing
- Reported sold
- $10.4M Offering amount: $10.4M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 29, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 12, 2015 | Initial | $10,399,876 | No comparison | 16 | SEC filing |
| Jun 12, 2015 | Initial | $6,009,268 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-241682
Source: Form D, filed Jun 12, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Oscar Buset | Executive |
| Florent Gros | Director |
| Jeffrey Hubbell | Director, Executive |
| Andre Mueller | Director |
| Jack Nielsen | Director |
| Harry Welten | Director |
| Thomas Woiwode | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
One Sansome Street, Suite 3630
San Francisco, CA, 94104
San Francisco, CA, 94104